Results 51 to 60 of about 1,204 (125)

Short-term treatment of CIDP with efgartigimod: a case series in China

Frontiers in Immunology
ObjectiveChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of autoimmune neuropathy with treatment challenges due to the limitations of standard of care therapies.
Chong Sun, Chong Sun, Chong Sun, Jianian Hu, Jianian Hu, Jianian Hu, Yanyin Zhao, Yanyin Zhao, Yanyin Zhao, Yongsheng Zheng, Yongsheng Zheng, Yongsheng Zheng, Quanhua Meng, Sushan Luo, Sushan Luo, Sushan Luo, Kai Qiao, Kai Qiao, Kai Qiao, Jian Sun, Jian Sun, Jian Sun, Jiahong Lu, Jiahong Lu, Jiahong Lu, Jie Lin, Jie Lin, Jie Lin, Chongbo Zhao, Chongbo Zhao, Chongbo Zhao   +30 more
doaj   +1 more source

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report

Frontiers in Immunology
IntroductionMyasthenia gravis (MG) is an autoimmune disorder primarily affecting the neuromuscular junction. Muscle-specific receptor tyrosine kinase antibody (MuSK-Ab)-mediated MG often presents with bulbar weakness and is prone to crisis.
Xiujun Zheng, Jing Wang, Tongtong Cai, Houshi Zhou   +3 more
doaj   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology
Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG).
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
doaj   +1 more source

Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series

Frontiers in Immunology
IntroductionEfgartigimod is effective and well-tolerated in patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG).
Jie Song, Haiyan Wang, Xiao Huan, Qilong Jiang, Zongtai Wu, Chong Yan, Jianying Xi, Chongbo Zhao, Huiyu Feng, Sushan Luo   +9 more
doaj   +1 more source

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

Frontiers in Pharmacology
ObjectiveEfgartigimod alfa, approved for treating generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, has uncertain long-term safety in large populations This study analyzed adverse events ...
Yunlin Yang, Jinfeng Liu, Wei Wei, Wei Wei, Wei Wei   +4 more
doaj   +1 more source

Open-label study of efgartigimod in seronegative myasthenia gravis

Therapeutic Advances in Neurological Disorders
Background: The ADAPT trial demonstrated the benefit of efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, in acetylcholine receptor antibody (AChRAb) positive patients with generalized myasthenia gravis (MG).
Mohamed Khateb, Ajith Sivadasan, Carolina Barnett-Tapia, Lubna Daniyal, Lahiru Fernando, Shiyi Chen, Leif Erik Lovblom, Hans Katzberg, Vera Bril   +8 more
doaj   +1 more source

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Brain and Behavior
Purpose of Review: This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on ...
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
doaj   +1 more source

Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis

Frontiers in Immunology
Anti-GQ1b antibody syndrome is a spectrum of autoimmune neurological disorders that includes Miller Fisher syndrome, Guillain-Barré syndrome (GBS) with ophthalmoplegia, Bickerstaff brainstem encephalitis, and acute ophthalmoplegia without ataxia.
Keiko Watanabe, Seiya Takahashi, Akane Kanda, Takuya Watanabe, Yuki Kakinuma, Satoshi Yano, Ryuta Kinno, Ryuta Kinno   +7 more
doaj   +1 more source

Efgartigimod-associated Kaposi’s varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review

Frontiers in Immunology
BackgroundEfgartigimod (Efgartigimod alpha fcab, Vyvgart™) is a pioneering neonatal Fc receptor (FcRn) antagonist for the treatment of severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG) autoantibodies, including myasthenia gravis ...
Lingzhi Ge, Yanyan Li, Ying Sun, Wenfang Chen, Xiaoli Ni, Xiaoli Ni, Fangli Wei, Zhen Mu   +7 more
doaj   +1 more source

Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study

Neurotherapeutics
Early intervention in impending myasthenic crisis (IMC) is critical to avert life-threatening progression. This study compared the clinical effectiveness and safety of the novel FcRn antagonist efgartigimod versus intravenous immunoglobulin (IVIg) in IMC
Rongjing Guo, Chao Sun, Xiaoxi Huang, Sijia Hao, Qingqing Wang, Zhe Ruan, Ting Gao, Yonglan Tang, Xiangqi Cao, Yu Liu, Zhuyi Li, Ting Chang   +11 more
doaj   +1 more source